<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02980536</url>
  </required_header>
  <id_info>
    <org_study_id>BerryGenomics NMB</org_study_id>
    <nct_id>NCT02980536</nct_id>
  </id_info>
  <brief_title>cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China</brief_title>
  <official_title>The Oncogenic Mutation Detection of Advanced NSCLC Patients by cSMART Liquid Biopsy and Dynamic Monitor of Tyrosine Kinase Inhibitor(TKI) Efficiency in Inner-Mongolia China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Berry Genomics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baotou Cancer Hospital Inner-Mongolia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Berry Genomics Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the mutation pattern of epidermal growth factor
      receptor (EGFR) and other TKI targeted gene during TKI treatment of advanced NSCLC patient
      with liquid biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the study, 200 advanced NSCLC patients will be recruited. All the patients will receive
      biopsy genotype assay and Circulating Single-Molecule Amplification and Resequencing
      Technology (cSMART) liquid biopsy. those patients who carry EGFR activating mutation and
      other TKI targeted activating mutation will receive TKI treatment. During the TKI treatment,
      every patients will take liquid biopsy assay to monitor the mutation status. the study will
      be ended when all the patients had a progressive disease (PD) in their targeted lesion
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The TKI resistance gene mutation pattern in plasma DNA of TKI treated patient</measure>
    <time_frame>1.5 years</time_frame>
    <description>The researcher would like to find out the change of mutation in plasma DNA of the patients who received TKI treatment by a liquid biopsy method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The concordance of gene mutation pattern between liquid biopsy and traditional cancer tissue biopsy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">129</enrollment>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <condition>Adenocarcinoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      There are two types of biospecimen collected in this study. One is the tumor tissue sample
      taken by biopsy. The other is the plasma sample from the blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Stage III and Stage IV NSCLC, adenocarcinoma.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NSCLC adenocarcinoma patients confirmed by pathologist

          -  Initial, non-operative patients with stage III &amp; IV adenocarcinoma

          -  Older than 18 years old

          -  Subjects have no major organ dysfunction. In detail, Liver Function: TBiL≤1.5 ULN (
             Upper Limit of Normal); Serum GPT (Glutamate-Pyruvate Transaminase ):≤2 ULN, Renal
             Function: ScR≤1.2 ULN; BUN≤1.2 ULN, BM (Bone Marrow) Reserve: WBC (White Blood cell
             Count) ≥4.0×e9/L; ANC≥2.0×e9/L，PLT≥100×e9/L，HGB≥100g/L.

        PS (Performance Status) Score: less than 2, Expected Survival Time: More than 3 months;

          -  Have a clear measurable tumor lesion in lung,under RIEST.

          -  Without severe drug allergy

          -  Patients participate in this trail must sign the informed consent

        Exclusion Criteria:

          -  Patients with brain metases related syndrome

          -  Patients with bone metases related complication

          -  Patients with cognitive disorder

          -  Patients with major organ dysfunction and severe cardiopathy include congestive
             heart-failure, uncontrolled arrhythmia, angina with long term treatment, VHD (Valvular
             Heart Disease), myocardial infraction, RHTN (Resistant Hypertension).

          -  Patients with other severe complication and excluded by the researcher.

          -  Patients who are allergy with the TKI in this trail.

          -  Patients who participated in other trails or with anti-tumor treatments

          -  Patients who receive radiotherapy at the site of curative effect observation

          -  Patients who receive allogenic blood transfusion within 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shun Lu, MD/PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baogang Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baotou Cancer Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Hospital Baotou</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baotou Centry Hospital</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <zip>014040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayan Nur Hospital</name>
      <address>
        <city>Bayan Nur</city>
        <state>Inner Mongolia</state>
        <zip>015000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Inner Mongolia Autonomous Region Cancer Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Inner Mongolia Autonomous Region People's Hospital</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Inner Monglia Medical University</name>
      <address>
        <city>Hohhot</city>
        <state>Inner Mongolia</state>
        <zip>010050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalad Banner People's Hospital</name>
      <address>
        <city>Ordos</city>
        <state>Inner Mongolia</state>
        <zip>104300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang Z, Cheng G, Han X, Mu X, Zhang Y, Cui D, Liu C, Zhang L, Fan Z, Ma L, Yang L, Di J, Cram DS, Shi Y, Liu D. Application of Single-Molecule Amplification and Resequencing Technology for Broad Surveillance of Plasma Mutations in Patients with Advanced Lung Adenocarcinoma. J Mol Diagn. 2017 Jan;19(1):169-181. doi: 10.1016/j.jmoldx.2016.09.008. Epub 2016 Nov 19.</citation>
    <PMID>27870944</PMID>
  </reference>
  <reference>
    <citation>Chai X, Ren P, Wei B, Ma J, Mai L, Cram DS, Song Y, Guo Y. A comparative study of EGFR oncogenic mutations in matching tissue and plasma samples from patients with advanced non-small cell lung carcinoma. Clin Chim Acta. 2016 Jun 1;457:106-11. doi: 10.1016/j.cca.2016.04.003. Epub 2016 Apr 9.</citation>
    <PMID>27071701</PMID>
  </reference>
  <reference>
    <citation>Song Y, Zhou X, Huang S, Li X, Qi Q, Jiang Y, Liu Y, Ma C, Li Z, Xu M, Cram DS, Liu J. Quantitation of fetal DNA fraction in maternal plasma using circulating single molecule amplification and re-sequencing technology (cSMART). Clin Chim Acta. 2016 May 1;456:151-156. doi: 10.1016/j.cca.2016.03.005. Epub 2016 Mar 15.</citation>
    <PMID>26993877</PMID>
  </reference>
  <reference>
    <citation>Lv W, Wei X, Guo R, Liu Q, Zheng Y, Chang J, Bai T, Li H, Zhang J, Song Z, Cram DS, Liang D, Wu L. Noninvasive prenatal testing for Wilson disease by use of circulating single-molecule amplification and resequencing technology (cSMART). Clin Chem. 2015 Jan;61(1):172-81. doi: 10.1373/clinchem.2014.229328. Epub 2014 Nov 6.</citation>
    <PMID>25376582</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>TKI</keyword>
  <keyword>Mutation</keyword>
  <keyword>Liquid Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

